# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
1 | 05-15-2024 | 03-31-2024 | 10-Q | |
2 | 03-25-2024 | 12-31-2023 | 10-K | |
3 | 11-13-2023 | 09-30-2023 | 10-Q | |
4 | 08-21-2023 | 06-30-2023 | 10-Q |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Denifanstat achieved statistically significant results on primary and secondary liver biopsy endpoints in the ITT population,...
Madrigal Pharmaceuticals and Sagimet Biosciences shares fall following Eli Lilly's presentation at the EASL Liver Congress ...
JMP Securities analyst Jonathan Wolleben reiterates Sagimet Biosciences (NASDAQ:SGMT) with a Market Outperform and maintains...
HC Wainwright & Co. analyst Ed Arce reiterates Sagimet Biosciences (NASDAQ:SGMT) with a Buy and maintains $32 price target.
Sagimet Biosciences Inc. ((Sagimet, NASDAQ:SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid syntha...
Goldman Sachs analyst Andrea Tan maintains Sagimet Biosciences (NASDAQ:SGMT) with a Buy and lowers the price target from $27...
HC Wainwright & Co. analyst Ed Arce reiterates Sagimet Biosciences (NASDAQ:SGMT) with a Buy and maintains $32 price target.
Sagimet Biosciences Inc. ((Sagimet, NASDAQ:SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid syntha...